0:00

Now there are, uh, different disease modifying, uh, drugs

0:03

that you have heard about so far.

0:05

Uh, AADA Helm is really, really a historical at this point

0:09

because, uh, umab

0:10

and Lecan have really outperformed, uh, AADA helm.

0:13

But these are all IgG monoclonal antibodies.

0:17

Now, all three of these drugs did a great job at their

0:19

secondary endpoints, which is

0:21

to clear beta amyloid plaque from the brain.

0:23

But when it comes to the primary endpoint,

0:26

which is slowing the rate of cognitive decline, um,

0:29

AADA Helm did not do as well.

0:31

So only in one trial they had 23%

0:33

improvement, but not in the other trial.

0:35

Donan actually had 35% slowing in cognitive decline.

0:39

Uh, their results of their trial were just recently released

0:42

in July, 2023,

0:44

and Lecan had 27% slowing of cognitive decline.

0:48

Um, now the price tag for Lecan is big at 26.5 K,

0:52

but you have to realize, you know, also that this is a,

0:55

uh, a lethal disease.

0:56

Um, and to be able to give time back to our loved ones, uh,

1:01

by slowing their rate of cognitive decline is a big deal.

1:04

And again, CMS is now covering, uh, as is the VA.

1:08

Now numerous other trials are also ongoing,

1:10

including disease prevention trials, such

1:13

as the dominantly inherited Alzheimer's network trials.

1:16

And then there are several trials

1:17

that include pharmacologic targeting

1:19

and monitoring of other disease biomarkers for Alzheimer's,

1:22

such as neurofibrillary tangles,

1:24

which can be imaged again with Tau pet.

1:26

Now, the National Institute of uh,

1:28

aging is currently funding more than 450

1:31

active clinical dementia trials.

1:33

So there is a lot of activity in this space.